Bipolar Disorder Clinical Trial
Official title:
Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
The investigators' hypothesis is that add-on varenicline will be effective (versus placebo)
in initiating abstinence from smoking in subjects with stable, euthymic bipolar disorder who
are motivated to quit smoking within four weeks. This primary outcome will be assessed from
randomization to 12 weeks or end of the treatment phase of the study. Secondarily, the
investigators also hypothesize that varenicline will prevent relapse in the subsequent
12-weeks follow-up non-treatment phase. Furthermore, the investigators plan to test the
effectiveness of varenicline in reducing nicotine withdrawal symptoms or urges to smoke, as
well as its safety for use in stable bipolar patients when used as an add-on treatment for
smoking cessation.
The investigators plan to test these hypotheses by conducting a randomized,
placebo-controlled add-on treatment trial of Chantix with 60 recruited subjects diagnosed
with DSM-IV bipolar disorder for a period of three months. The investigators will follow-up
with them three months later to evaluate extended abstinence.
OBJECTIVE:
Our primary objective is to determine if adjunctive varenicline will be efficacious (vs.
placebo) in initiating abstinence from smoking cigarettes in subjects with stable bipolar
disorder who are motivated to quit smoking during a 12-week treatment phase. A secondary
outcome is to determine whether those who initiated abstinence during the 12-week treatment
phase will maintain abstinence in the subsequent three-month follow-up period off study
medications.
Additional outcomes: we plan to test the effectiveness of varenicline in reducing nicotine
withdrawal symptoms or urges to smoke, as well as its safety for use in stable bipolar
patients when used as an adjunctive treatment for smoking cessation.
RESEARCH PLAN:
We plan to test these hypotheses by conducting a randomized, placebo-controlled, treatment
trial of Chantix. Measures of CO levels in expired air (10 ppm or lower), self-reported
abstinence, and psychopathology ratings will be used to evaluate primary and secondary
outcomes along with safety assessments. Smoking abstinence is defined as 7-day point
prevalence of self-reported no smoking verified objectively by expired CO levels of 10 ppm or
less, and will be assessed at 12-weeks (or end of treatment phase) as the primary outcome.
The same criterion will be used to assess maintenance of abstinence in the non-treatment
phase, i.e. at 24 weeks or end of study.
METHODS:
Seventy-six subjects with DSM-IV bipolar disorder will be recruited from Western Psychiatric
Institute and Clinic and Dubois Regional Medical Center. Using a 1:1 Randomization, which
also takes into account gender, subjects who sign an informed consent document will be
randomized to receive Chantix or placebo.
It is expected that 16 of the 76 may not meet inclusion/exclusion criteria, leaving 60
consenting adults aged 18-65 years with DSM-IV bipolar disorder, which will be confirmed by
the MINI (Sheehan et al.) Subjects must meet smoking inclusion criteria of smoking 10 or more
cigarettes per day. Motivation to quit smoking (score of at least 7 on the Contemplation
Ladder Scale) as well as stable mood status (Young Mania Rating Scale score of eight or less,
Montgomery Asberg Depression Rating Scale Score of eight or less, with low scores on suicide
aggression and psychotic items over a four-week period required. Subjects who have received
pharmacological agents for smoking cessation such as bupropion, nicotine replacement
treatment, or who have participated in behavioral treatment for smoking cessation more than
three months before beginning the study will be permitted to enroll in the study. Anyone
experiencing serious side-effects from varenicline in the past or who has already
participated in a smoking cessation study with varenicline will be excluded.
Chantix or placebo will be administered using random assignment at a dose of 0.5 mg by mouth
for three days, followed by 0.5 mg twice per day for four days. After the first week, the
dose will be increased to 1 mg twice daily for 11 weeks. Subjects must be able to tolerate a
minimum of 1 mg per day to continue in the study.
Subjects will pick a target date between visit 3 (to permit titration to the target dose of 2
mg per day) and visit 4 to quit smoking. There needs to be at least 24 hours (preferably 48)
between the time of the last cigarette usage and visit 4, where a CO measurement will be
taken.
Those who are unable to quit at this time will be given an opportunity to pick additional
quit dates. All visits will be scheduled a week apart and subjects will continue to take
their double-blind medication and receive counseling sessions for smoking cessation. Study
medication will be stopped after 12 weeks, and there will be weekly visits to evaluate
abstinence.
Some standard psychopathology rating scales and smoking rating scales will be administered to
evaluate secondary aims such as the degree of nicotine withdrawal symptoms and the impact of
residual symptoms on bipolar disorder. Safety will be assessed through the administration of
specific mania and depression rating scales including and the Columbia -Suicide Severity
Rating Scale, as well as a comprehensive health assessment. This includes a medical history
and evaluation of laboratory measures. Any adverse effects of medication will be assessed by
asking questions at each visit and if necessary, contacting the subject by phone outside the
scheduled visits.
SIGNIFICANCE The rate of cigarette smoking among people with psychiatric disorders remains
exceedingly high; nearly two to four times as high as those in the general population.
Patients with bipolar disorder may have the highest rates of smoking as compared with people
with other psychiatric diagnoses. To date, there have been no treatment trials of adequate
size to measure smoking cessation rates in people with bipolar disorder. If varenicline
proves to be an effective in helping people with bipolar disorder to stop smoking, or even to
reduce their smoking rates, this could play an important role in improving their health.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |